Z6尊龙凯时

CARsgen Therapeutics Completes $30 Million Series B Financing

CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion